

0360
#6
PATENTS

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No.: 47508.514 / HYZ-075 US2)

Applicant: Agrawal et al.

Serial No.: 09/825,489

Filing Date: April 3, 2001

Title: Sensitization of Cells to Cytotoxic Agents Using Oligonucleotides
Directed to Nucleotide Excision Repair of Transcription Coupled
Repair Genes

Examiner: Not Yet Assigned


Group Art Unit: Not Yet Assigned

Assistant Commissioner for Patents
Washington, D.C. 20231

CERTIFICATE UNDER 37 CFR 1.8(a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231 on the date set forth below.

5/13/02
Date of Signature and of
Mail Deposit


Patricia J. Byrnes

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
WITH STATEMENT UNDER 37 C.F.R. § 1.97(e)(1)**

Dear Sirs:

Applicant and their legal representatives hereby make of record on the attached PTO Form-1449 the following publications which are known to them and considered warranting disclosure under 37 C.F.R. §1.56. Copies of each of these publications are enclosed.

Applicant states under 37 C.F.R. §1.97(e)(1) that the publications were cited in an International Search Report issued in connection with a counterpart Patent Cooperation Treaty application No. PCT/US01/10800 not more than three months prior to the filing of this statement. Also enclosed is a copy of the International Search Report for the Examiner's review.

PATENTS

It is respectfully requested that the information above be expressly considered during the prosecution of this application and that the publications be made of record therein and appear among the "References Cited" on any patent to issue therefrom. In this regard, it is requested that the Examiner initial and return a copy of the enclosed Form PTO-1449 with the next Patent Office Communication.

This submission does not represent that a search has been made and does not constitute an admission that the listed documents are material to patentability or that the listed documents are prior art. If it should be determined that any of the listed documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits and is therefore submitted as both timely and proper; therefore, no fees are believed to be due.

The Commissioner, however, is hereby authorized to charge any fees necessary to maintain the pendency of this application to Deposit Account No. 08-0219.

Respectfully submitted,

Date:

May 13 2002

Ann-Louise Kerner

Ann-Louise Kerner, Ph.D.

Registration No. 33,523

Attorney for Applicant

Hale and Dorr LLP
60 State Street
Boston, Massachusetts 02109
Tel: (617) 526-6192
Fax: (617) 526-5000



Subt. For, PTO-1449

INFORMATION DISCLOSURE
IN AN APPLICATION

(Use several sheets if necessary)

Sheet

1

OF

1

Docket Number
47508.514
(HYZ-075 US2)Application Number
09/825,489Applicant
Agrawal et al.Filing Date
April 3, 2001Group Art Unit
Not Yet Assigned

U.S. Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

Foreign Patent Documents

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 97/32604	09/1997	PCT				

Other Documents (Including Author, Title, Date Pertinent Pages, Etc.)

	A1	<i>Proc. Amer. Assoc. Can. Res.</i> , #4085 "Mixed Backbone Oligonucleotides Targeting the Nucleotide Excision Repair Protein XPA Potentiate Cisplatin Cytotoxicity", vol. 41, March 2000.
	A2	Tortora, G. et al., <i>Proc. Natl. Acad. Sci. USA</i> , "Synergistic Inhibition of Human Cancer Cell Growth by Cytotoxic Drugs and Mixed Backbone Antisense Oligonucleotide Targeting Protein Kinase A", 94:12586-12591, November 1997.
	A3	Bianco, C., <i>Proc. 41st Annual ASTRO Meeting</i> , #28 "Synergistic Antiproliferative Effects of Ionizing Radiations With Anti-Epidermal Growth Factor Receptor Monoclonal Antibody C225 and Protein Kinase A Antisense Oligonucleotide HYB 165".
	A4	
	A5	
	A6	
	A7	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.